CSPIA
KNSA icon

Cary Street Partners Investment Advisory’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,000
Closed -$17.4K – 1277
2023
Q3 		$17.4K Hold
1,000
– – ﹤0.01% 1160
2023
Q2 		$14.1K Buy
+1,000
New +$13.4K ﹤0.01% 1147

Other funds holding KNSA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Cary Street Partners Investment Advisory's KNSA Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2023, closing a stake of 1,000 shares — an estimated $17.4K sold.

Cary Street Partners Investment Advisory first reported a position in KNSA in Q2 2023 and held it in 2 quarters. The position peaked at $17.4K in Q3 2023. 142 funds tracked by Wall St. Rank hold KNSA as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Kiniksa Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 1,000 Kiniksa Pharmaceuticals shares in Q4 2023, an estimated $17.4K.
  • Cary Street Partners Investment Advisory first reported a position in Kiniksa Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Cary Street Partners Investment Advisory's Kiniksa Pharmaceuticals position peaked at $17.4K in Q3 2023.
  • 142 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.